135785 20260217205550.0 doi 10.1016/j.ijbiomac.2024.132563 sideral 138750 ART-2024-138750 eng Landa, Guillermo (orcid)0000-0003-1599-8216 PLGA nanoparticle-encapsulated lysostaphin for the treatment of Staphylococcus aureus infections 2024 Access copy available to the general public Unrestricted Staphylococcus aureus possesses the ability to become pathogenic, leading to severe and life-threatening infections. Its methicillin-resistant variant MRSA has garnered high-priority status due to its increased morbidity and associated mortality. This emphasizes the urgency for novel anti-staphylococcal agents. The bacteriocin lysostaphin stands out for its remarkable bactericidal activity against S. aureus, including MRSA, outperforming conventional antibiotics. However, the clinical application of lysostaphin faces challenges, including enzymatic activity loss under physiological conditions and potential immunogenicity. This study introduces a novel approach by encapsulating lysostaphin within polylactic-co-glycolic acid (PLGA) nanoparticles, a biodegradable copolymer known for its biocompatibility and sustained drug release ability. The study assesses the antimicrobial activity of lysostaphin-loaded PLGA nanoparticles against different S. aureus strains, and we also used GFP-expressing S. aureus for facilitating its traceability in planktonic, biofilm, and intracellular infection models. The results showed the significant reduction in bacteria viability both in planktonic and biofilm states. The in vitro intracellular infection model demonstrated the significantly enhanced efficiency of the developed nanoparticles compared to the treatment with the free bacteriocin. This research presents lysostaphin encapsulation within PLGA nanoparticles and offers promising avenues for enhancing lysostaphin's therapeutic efficacy against S. aureus infections. info:eu-repo/grantAgreement/ES/ISCIII/MS19-00092 info:eu-repo/grantAgreement/ES/MCINN/PRE2018-085769 info:eu-repo/grantAgreement/ES/MICINN/PDC2021-121405-I00 info:eu-repo/grantAgreement/ES/MICINN/PID2020-113987RB-I00 info:eu-repo/semantics/openAccess by-nc-nd https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es 8.5 2024 BIOCHEMISTRY & MOLECULAR BIOLOGY 29 / 320 = 0.091 2024 Q1 T1 POLYMER SCIENCE 6 / 94 = 0.064 2024 Q1 T1 CHEMISTRY, APPLIED 8 / 76 = 0.105 2024 Q1 T1 1.285 2024 Biochemistry 2024 Q1 Biomaterials 2024 Q1 Food Science 2024 Q1 Molecular Biology 2024 Q2 Structural Biology 2024 Q2 10.3 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Aguerri, Laura Universidad de Zaragoza (orcid)0000-0002-5309-7796 Irusta, Silvia (orcid)0000-0002-2966-9088 Mendoza, Gracia (orcid)0000-0003-2293-363X Arruebo, Manuel Universidad de Zaragoza (orcid)0000-0003-3165-0156 2009 750 Universidad de Zaragoza Dpto. Química Analítica Área Química Analítica 5005 555 Universidad de Zaragoza Dpto. Ing.Quím.Tecnol.Med.Amb. Área Ingeniería Química 271, Part 1 (2024), 132563 [11 pp.] Int. j. biol. macromol. International journal of biological macromolecules 0141-8130 5405372 http://zaguan.unizar.es/record/135785/files/texto_completo.pdf Versión publicada 2534872 http://zaguan.unizar.es/record/135785/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:135785 articulos driver 2026-02-17-20:39:57 ARTICLE